Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.50 |
| ▸ | CA1 | P00915 | 5/20 | 0.46 |
| ▸ | CA2 | P00918 | 5/20 | 0.46 |
| ▸ | CA12 | O43570 | 3/20 | 0.46 |
| ▸ | CA9 | Q16790 | 3/20 | 0.46 |
| ▸ | CA3 | P07451 | 1/20 | 0.46 |
| ▸ | CA6 | P23280 | 1/20 | 0.46 |
| ▸ | CA5A | P35218 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.46 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.42 |
| ▸ | MMP1 | P03956 | 1/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | MMP9 | P14780 | 1/20 | 0.42 |
| ▸ | MMP8 | P22894 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28577615 | 0.86 | GAA (0.59) | GAACA1CA2CA12CA9 | |
| SCHEMBL13783355 | 0.80 | GAA (0.52) | GAACA1CA2CA12CA9 | |
| SCHEMBL6547519 | 0.78 | GAA (0.50) | GAACA1CA2CA12CA9 | |
| SCHEMBL28433392 | 0.77 | CA2 (0.60) | GAACA1CA2CA12CA9 | |
| SCHEMBL2499107 | 0.77 | GAA (0.48) | GAACA1CA2CA12CA9 | |
| SCHEMBL9770800 | 0.75 | GAA (0.46) | GAACA1CA2CA12CA9 | |
| SCHEMBL6585722 | 0.75 | GAA (0.56) | GAACA1CA2CA12CA9 | |
| SCHEMBL28439929 | 0.74 | CA2 (0.51) | GAACA1CA2CA12CA9 | |
| SCHEMBL118977 | 0.73 | GAA (0.54) | GAACA1CA2CA12CA9 | |
| SCHEMBL1721592 | 0.73 | GAA (0.54) | GAACA1CA2CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4626554-A1 | GLUTARIMIDE-CONTAINING KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF | Tiger Biotherapeutics Inc. (US) | 2025-10-08 | — | — | EP | disclosed |
| US-12168058-B2 | Glutarimide-containing KRAS-mutant degrader compounds and uses thereof | Tiger Biotherapeutics, Inc. (US) | 2024-12-17 | — | — | US | disclosed |
| US-20240216516-A1 | GLUTARIMIDE-CONTAINING KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF | TIGER BIOTHERAPEUTICS INC. | 2024-07-04 | — | — | US | disclosed |
| US-20240216516-A1 | GLUTARIMIDE-CONTAINING KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF | TIGER BIOTHERAPEUTICS INC. | 2024-07-04 | — | — | US | disclosed |
| WO-2024118960-A1 | GLUTARIMIDE-CONTAINING KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF | TIGER BIOTHERAPEUTICS INC. (US) | 2024-06-06 | — | — | WO | disclosed |
| EP-3681862-B1 | BETA-HYDROXY HETEROCYCLIC AMINES AND THEIR USE IN THE TREATMENT OF HYPERGLYCAEMIA | ATROGI AB (SE) | 2023-11-08 | — | — | EP | disclosed |
| US-11427539-B2 | Beta-hydroxy heterocyclic amines and their use in the treatment of hyperglycaemia | ATROGI AB (SE) | 2022-08-30 | — | — | US | disclosed |
| US-20200277259-A1 | BETA-HYDROXY HETEROCYCLIC AMINES AND THEIR USE IN THE TREATMENT OF HYPERGLYCAEMIA | ATROGI AB (SE) | 2020-09-03 | — | — | US | disclosed |
| EP-3681862-A1 | BETA-HYDROXY HETEROCYCLIC AMINES AND THEIR USE IN THE TREATMENT OF HYPERGLYCAEMIA | Atrogi AB (SE) | 2020-07-22 | — | — | EP | disclosed |
| CN-111164072-A | β -hydroxy heterocyclic amines and their use in the treatment of hyperglycaemia | 阿托基公司 | 2020-05-15 | — | — | CN | disclosed |
| WO-2019053425-A1 | BETA-HYDROXY HETEROCYCLIC AMINES AND THEIR USE IN THE TREATMENT OF HYPERGLYCAEMIA | ATROGI AB (SE) | 2019-03-21 | — | — | WO | disclosed |
| US-8030300-B2 | 2-pyrrolidinyloxy-substituted pyridine; Alzheimer's disease, Parkinson's disease, dyskinesias, Tourette's syndrome, schizophrenia, attention deficit disorder, anxiety, pain, depression, obsessive compulsive disorder | GEORGETOWN UNIVERSITY (US) | 2011-10-04 | — | — | US | disclosed |
| US-8030300-B2 | 2-pyrrolidinyloxy-substituted pyridine; Alzheimer's disease, Parkinson's disease, dyskinesias, Tourette's syndrome, schizophrenia, attention deficit disorder, anxiety, pain, depression, obsessive compulsive disorder | GEORGETOWN UNIVERSITY (US) | 2011-10-04 | — | — | US | disclosed |
| US-20080132486-A1 | Ligands for Nicotinic Acetylcholine Receptors, and Methods of Making and Using Them | GEORGETOWN UNIVERSITY (US) | 2008-06-05 | — | — | US | disclosed |
| US-20080132486-A1 | Ligands for Nicotinic Acetylcholine Receptors, and Methods of Making and Using Them | GEORGETOWN UNIVERSITY (US) | 2008-06-05 | — | — | US | disclosed |
| WO-2005000806-A2 | LIGANDS FOR NICOTINIC ACETYLCHOLINE RECEPTORS, AND METHODS OF MAKING AND USING THEM | GEORGETOWN UNIVERSITY (US) | 2005-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240216516-A1 | GLUTARIMIDE-CONTAINING KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF | KRAS, VHL, HRAS | GAA 32/4885CA1 2780/4885CA2 1408/4885 |
| US-20080132486-A1 | Ligands for Nicotinic Acetylcholine Receptors, and Methods of Making and Using Them | CHRNA5, OPRL1, TAAR5 | GAA 512/4885CA1 3372/4885CA2 4430/4885 |
| US-20200277259-A1 | BETA-HYDROXY HETEROCYCLIC AMINES AND THEIR USE IN THE TREATMENT OF HYPERGLYCAEMIA | SLC5A1, GPR119, SLC5A2 | GAA 308/4885CA1 2898/4885CA2 2729/4885 |
| US-11427539-B2 | Beta-hydroxy heterocyclic amines and their use in the treatment of hyperglycaemia | SLC5A1, GPR119, SLC5A2 | GAA 308/4885CA1 2898/4885CA2 2729/4885 |
| US-12168058-B2 | Glutarimide-containing KRAS-mutant degrader compounds and uses thereof | KRAS, VHL, HRAS | GAA 32/4885CA1 2780/4885CA2 1408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.